Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 3Paresthesia 2Neurotoxicity Syndromes 2Neoplasm Metastasis 2

Interventions

Paclitaxel 7Oxaliplatin 6Vincristine 4Radiotherapy 4Leucovorin 4Carboplatin 4Amifostine 4Taxes 3Sodium Chloride 3Procarbazine 3Methotrexate 3Fluorouracil 3Cytarabine 3xaliproden 2glucarpidase 2Rituximab 2Radiotherapy, Intensity-Modulated 2Radiotherapy, Conformal 2Prednisolone 2Magnesium Sulfate 2Duloxetine Hydrochloride 2Dexamethasone 2Cyclophosphamide 2Cisplatin 2Calcium Gluconate 2Acupuncture Therapy 2neurotropin 1motexafin gadolinium 1haloperidol decanoate 1glutamic acid diethyl ester 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Neurotoxicity Syndromes × xaliproden × Clear all
NCT00305188 2016-05-04

Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.

Sanofi

Phase 3 Completed
879 enrolled
Gastrointestinal

Neoplasm Metastasis, Paresthesia, Colorectal Neoplasms, Neurotoxicity Syndromes

NCT00272051 2006-09-13

XENOX - Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy

Sanofi

Phase 3 Completed
620 enrolled
Gastrointestinal

Neoplasm Metastasis, Paresthesia, Colorectal Neoplasms, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡